TriStar is a biotechnology company specializing in the provision of quality annotated human oncology biospecimens and integrated, in-house contract research services (IHC, RNA-ISH, WES & RNAseq) for pharma, biotech, and diagnostic developers. Our ethically approved anonymized clinical samples acquired via collaborations with leading UK & European medical centers include pre/post SOC & immunotherapy, and incorporate clinical follow-up, survival & response information. TriStar’s expansive collection of FFPE blocks, tissue microarrays (TMAs), plasma, and digital images include IHC, NGS, RNAseq, GeoMx DSP & CODEX characterized specimens to facilitate a deeper understanding of tumor immune biology and to support drug development research in oncology & immuno-oncology.

Akamis Bio is a clinical-stage oncology company aiming to transform treatment of advanced solid tumors by designing novel, systemically administered viruses that can deliver potent, immunomodulatory therapeutics directly into tumors to treat previously intractable cancers.

Picture Health creates multimodal AI biomarkers for precision oncology via our proprietary Px Platform with next-generation radiomics capabilities.  Our advanced radiomic and pathomic imaging features, demonstrated in over 80 peer reviewed papers, are tied to interpretable biological tumor characteristics. Picture Health partners with biopharma companies to improve patient characterization & selection using small datasets from Phase 1 and 2 clinical trials. The Px Platform enables us to develop custom predictive AI biomarkers tailored to a specific indication. For more information, go to https://picturehealth.com/

N-Power Medicine is expanding access to oncology clinical trials across a network of community practices. N-Power Medicine provides clinical research infrastructure, including staff and technology, across all patients. This supports sites by standardizing high-quality data in a real-time registry at the point of care, facilitating patient identification and clinical trial conduct. For more information, go to https://www.npowermedicine.com/

Connecting the world with the right doctors, and doctors to a world of research. The trusted source of truth for global healthcare professional (HCP), clinical, scientific, and research information for life sciences, payors, providers, and patients. For more information, go to https://h1.co/

CRIO revolutionizes clinical research with cutting-edge cloud technology. CRIO enables remote monitoring and instant data review with CRIO Reviewer, an integrated eSource/EDC solution. Capturing data in real-time and ensuring compliance with various regulations, including 21 CFR 11, ICH-GCP, GDPR, and HIPAA, CRIO eliminates redundant data entry and safeguards data integrity. For more information, please visit https://clinicalresearch.io/

Bold thinking. Bolder actions. We are Medtronic.

We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world.

In everything we do, we are engineering the extraordinary.

EvolveImmune Therapeutics is a development-stage immune-oncology company which is pioneering an entirely new category of Precision Oncology medicines designed to overcome cancer cell resistance to current anti-tumor therapies. Our proprietary EVOLVE trispecific T cell engager platform fully integrates T cell costimulation through the CD2 receptor in a single biotherapeutic molecule, to optimize T cells for deep and durable clinical responses. To learn more, please visit https://evolveimmune.com.

IN8bio is a clinical-stage biopharmaceutical firm that specializes in advancing gamma-delta T cell therapies to achieve its mission of CANCER ZERO, the safe elimination of all cancer cells in every patient. The company’s DeltEx platform uses allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies designed to effectively identify and eradicate tumor cells. It has three lead product candidates in clinical trials for glioblastoma and leukemia (INB-400, INB-200, INB-100), and a portfolio of preclinical programs for solid tumors.

For over 20 years, Valos Srl has been seen as a foremost organization in the field of biostatistics and data managment services for Phase I-IV Clinical Trials. With professional experience in drug and device development studies, VALOS offers operational excellence and tailored services while providing high quality research to bolster clients' resounding successes. With a powerhouse team in place, in-depth knowledge of the pharmaceutical and biotech industries and intensive experience, VALOS aims to support its pharma clients set new benchmarks in clinical trials and scale newer heights.

At Jabil, we are proud to be a trusted partner for the world's top brands, offering comprehensive engineering, manufacturing, and supply chain solutions. With over 50 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe. Discover more at www.jabil.com.